Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.52 |
| ▸ | PPARG | P37231 | 8/20 | 0.52 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971145 | 1.00 | PPARA (0.52) | PPARAPPARGPPARDPTPN1ALDH1A1 | |
| SCHEMBL3971738 | 1.00 | PPARA (0.52) | PPARAPPARGPPARDPTPN1ALDH1A1 | |
| SCHEMBL11993009 | 0.89 | PPARA (0.53) | PPARAPPARGPPARDPTPN1SLC6A9 | |
| SCHEMBL3967738 | 0.89 | PPARG (0.62) | PPARAPPARGPTPN1SLC6A9 | |
| SCHEMBL3973024 | 0.88 | PPARG (0.46) | PPARAPPARGPPARDALDH1A1PTGES | |
| SCHEMBL6902221 | 0.88 | PPARA (0.47) | PPARAPPARGPPARDPTPN1ALDH1A1 | |
| SCHEMBL11993021 | 0.86 | PPARG (0.51) | PPARAPPARGPPARDPTPN1SLC6A9 | |
| SCHEMBL6904075 | 0.86 | PPARA (0.40) | PPARAPPARGPPARDPTPN1ALDH1A1 | |
| SCHEMBL3976202 | 0.86 | PPARG (0.51) | PPARAPPARGPPARDPTPN1SLC6A9 | |
| Pemaglitazar SCHEMBL6902223 | 0.85 | PPARA (0.52) | PPARAPPARGPPARDPTPN1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412326-B1 | BUTYRIC ACID DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-08-22 | — | — | EP | disclosed |
| US-7491747-B2 | 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes | MERCK PATENT GMBH (DE) | 2009-02-17 | — | — | US | disclosed |
| US-20050020651-A1 | Butyric acid derivatives | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020651-A1 | Butyric acid derivatives | GPR119, DBI, GABRB1 | PPARA 425/4885PPARG 492/4885PPARD 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.